Clinical News

Clinical Status

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">IDEC-152: Began Phase I trial</h1><div class="byline">WIR Staff</div><div class="date"></div></div></div></div>

VTJGc2RHVmtYMThsMTRpY2orR25TbVpTRHA2ZWV5bnZ5b0FWOHVrZXM3a044WjQydDI4U2kwcUhoS01yL0NvRXh2dEx4ZGphNDBvY2E3cWlCc2xqTDNYMmNuYi9ROWU5SHVtVWpYRUcwMk1TK3IzQ0hueGUyV3ZiZURIUkpLZTZpaElhRU5jcVJmMGlqcGFDVTRzb0p6R1ZhdVRYWmhPb1h5Z1NYWC9hODNRcTJoY3hOaGVrUWpJdkwybm9MNkVKOEt1QWd2TUY4NWZOMTZXODZEbXcxYkFNQ3B2NHJneTZQUFU1NEhaZ0V4a1NnM2JYZjVTYm5qQm40Y3FETFd6UDdOODU5NVY3SC9XZUUrdERTaTByaS9qYzlXZzdUbXZrSGRzWjJPcHcxRGV3TVgyS1JSWHRLQ1llbDlmdGxDNEZ0RVlhcjVzMzFaaU1EWVVEQm5HNEdNSnVseW5PQmR1UW5yajRYVEwxcXJFWVlaNHJudUY3b1BtT2JSZXpUeEVSVFQwMk5tOUdRdk93RnZBRTFHY3hBSStLUnU1b1lKZnlqTi9vUGcyelVCTkR0UEswL1g2dUkrZ3MwQ2xJazRvczQzNkd5RWdIQUlrOVRndjU3bmtLTmxaM3Bid2JvNlFnbUk4czcrMmg1LzNjOEt2ZGlqQ2pQMFMyUmhOVUlaZTk2MmJKLzdjaW1wcGp6VTBJMG9Xamh4aWZhUEZwQ1l3eDZ6d3ZFMkJTYmE3cEdGVFlPODljVUR6Q1NMc1J1dGdDVzlSV0h3Y0h6R2owWE1QZThtd0Iya2I4YmZ1M1p6TlRQTzhSWStYNkdiNTM1d1ZpcThkRnYyK2cwUDIwNmdYYzhHc01admQwSXJybHNPb3VzVDJuVkJmc1dyZEFQWUhBZzdEc0dzTGJaUnFoc3R2dVNncVg3dDFMaGp0cmRUbE9HZlMyeW4xVitrcHdLbm9rNHBTYjJqQndMY1BnaVlBa2ViRlRYamw4OWtOa0FTeVlGQTJmMytpMGJ5bFF6RXRGeXdUamg1V0FzSDN4YndWMHhiQmwxZEk1V1M4blVIMkZqVmE2UmpDaXptZGU5Smp6NUZHc0gxeEdtQmZzZ1dpcFlHdWpuekxJWGt5YzNxSDRYdkR4dGpGUDllNDVCa1JJQSswMUhkQXhhM0lUMDNsb0NHZ2lrOFZ3b3B6VmZ2dkZpZjNSbkZVUGRiMlgwQkpTRjVjdjIzWDBOa0NMaXJXcnlTaUNiWE44K2Q2Y1pYMjJVL2s2aHRvT01hcE82NmJvdytZMzJSdG9kaFEyTEdhdktRaTFwMzdqY2VHQkh3OUxFYmNVN1FrSW1YcVJZdnp1ZlJhYkowMXMyeGM2UWhBVFM1UEp4YURyM2laYVQ2UmJWQmx6REVsVDhrSURRYzdiSVVQaHNOSFVMM0lMeGpDNmFDaTByMGQ4VWZCUXdPZzZMNHRwQ0ZoZXdjeVVwMVo4TXppZC9HMEdzbWJSZTBmMzhNY1JZWUtBSTZHYXNzbjVoV29YcGZkMENHdnhRbWJoSnFUeVZ0dlNoYnphK1VPVzFkL0hPMzVXUG4vL2V2L2xvc0RkYkluM25Dd3ZXdDFnRnJ0Y2hTb3RXVmQ4cHNoaw==

Idec Pharmaceuticals Corp. (IDPH), San Diego, Calif. Product: IDEC-152 Business: Autoimmune/Inflammation Therapeutic category: Antibody Target:  CD23 recep...

autoimmune

Inflammation

IDEC-152: Began Phase I trial

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Discovery & Translation Analysis

Discovery & Translation

Hot Topics

BioCentury Podcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

East-West Healthcare Reception

Bio€quity Europe

Grand Rounds — U.S.

Grand Rounds — Europe

The BioCentury-BayHelix China Healthcare Summit

China Healthcare Summit

At the East-West Summit, you will meet key players looking to globalize innovation from across Asia.